Market Closed -
Other stock markets
|
After market 12:01:07 pm | |||
5 EUR | +2.56% | 5.003 | +0.06% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Sales 2023 | 2.23M 2.37M | Sales 2024 * | 37.83M 40.34M | Capitalization | 105M 112M |
---|---|---|---|---|---|
Net income 2023 | -23M -24.53M | Net income 2024 * | -5M -5.33M | EV / Sales 2023 | 36.2 x |
Net Debt 2023 * | 33.7M 35.94M | Net Debt 2024 * | 46.6M 49.69M | EV / Sales 2024 * | 4.01 x |
P/E ratio 2023 |
-3.63
x | P/E ratio 2024 * |
-11.3
x | Employees | 62 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 72.4% |
Latest transcript on OSE Immunotherapeutics
1 day | -0.41% | ||
1 week | +3.30% | ||
Current month | -0.10% | ||
1 month | -0.10% | ||
3 months | +36.38% | ||
6 months | +9.22% | ||
Current year | +13.43% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 16-05-30 |
Director of Finance/CFO | - | 16-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Director/Board Member | 66 | 23-06-21 | |
Director/Board Member | 66 | 22-02-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 5 | +2.56% | 128 837 |
24-04-17 | 4.875 | +4.84% | 248,766 |
24-04-16 | 4.65 | +0.76% | 51,090 |
24-04-15 | 4.615 | -2.02% | 46,010 |
24-04-12 | 4.71 | +0.21% | 51,163 |
Real-time Euronext Paris, April 18, 2024 at 09:18 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.43% | 112M | |
-1.78% | 41.36B | |
+43.68% | 41.3B | |
+4.01% | 39.61B | |
-15.14% | 25.62B | |
+3.16% | 24.09B | |
-24.08% | 18.38B | |
+24.76% | 11.85B | |
-2.67% | 11.82B | |
+7.01% | 11.07B |
- Stock Market
- Equities
- OSE Stock